SCHEMBL97511

SCHEMBL97511

C1CC(N(C2CCC2)C2CCC2)C1

nearest known ligand 0.39

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
ADH1A P07327 6/20 0.39
ADH1C P00326 4/20 0.39
ADH4 P08319 1/20 0.35
PHGDH O43175 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL64029 0.95 ADH1A (0.42) ADH1AADH1CADH4PHGDH
SCHEMBL99438 0.91 ADH1A (0.43) ADH1AADH1CADH4PHGDH
SCHEMBL97243 0.91 ADH1A (0.43) ADH1AADH1CADH4PHGDH
SCHEMBL19591971 0.91 ADH1A (0.43) ADH1AADH1CADH4PHGDH
SCHEMBL11277355 0.91 ADH1A (0.43) ADH1AADH1CADH4PHGDH
SCHEMBL19592023 0.91 ADH1A (0.43) ADH1AADH1CADH4PHGDH
SCHEMBL19997015 0.91 ADH1A (0.43) ADH1AADH1CADH4PHGDH
SCHEMBL65968 0.91 ADH1A (0.43) ADH1AADH1CADH4PHGDH
SCHEMBL21289754 0.91 ADH1A (0.43) ADH1AADH1CADH4PHGDH
SCHEMBL19591972 0.91 ADH1A (0.43) ADH1AADH1CADH4PHGDH

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-110627832-A Preparation method for synthesizing tenofovir alafenamide by oxidation method 江西农业大学 2019-12-31 CN claimed
CN-110551153-A Preparation method for synthesizing tenofovir alafenamide by three-step method UNIV JIANGXI AGRICULTURAL 2019-12-10 CN claimed
CN-110627832-A Preparation method for synthesizing tenofovir alafenamide by oxidation method 江西农业大学 2019-12-31 CN disclosed
CN-110590844-A Preparation method for synthesizing tenofovir alafenamide by two-step method 江西农业大学 2019-12-20 CN disclosed
CN-110551153-A Preparation method for synthesizing tenofovir alafenamide by three-step method UNIV JIANGXI AGRICULTURAL 2019-12-10 CN disclosed
EP-2076558-B1 COMPOSITION COMPRISING NEOPENTASILANE AND METHOD OF PREPARING SAME DOW CORNING (US) 2018-04-18 EP disclosed
EP-2067770-B1 PROCESS FOR PRODUCTION OF SULFONIC ACID ESTER WAKO PURE CHEM IND LTD (JP) 2017-04-12 EP disclosed
EP-2602856-B1 NONAQUEOUS ELECTROLYTE SOLUTION AND NONAQUEOUS ELECTROLYTE BATTERY USING SAME WAKO PURE CHEM IND LTD (JP) 2017-02-22 EP disclosed
US-9257720-B2 Nonaqueous electrolyte solution and nonaqueous electrolyte battery using same WAKO PURE CHEMICAL INDUSTRIES, LTD. (JP) 2016-02-09 US disclosed
US-9206106-B2 Production method of carbonyl compound KUREHA CORPORATION (JP) 2015-12-08 US disclosed
US-9190695-B2 Nonaqueous electrolyte solution, method for producing same, and nonaqueous electrolyte battery using the electrolyte solution WAKO PURE CHEMICAL INDUSTRIES, LTD. (JP) 2015-11-17 US disclosed
US-20100324314-A1 PROCESS FOR PRODUCING ESTER COMPOUND WAKO PURE CHEMICAL INDUSTRIES, LTD. (JP) 2010-12-23 US disclosed
EP-2248821-A1 SUBSTRATE FOR ASSAYING -GLUCAN AND/OR ENDOTOXIN AND ASSAY METHOD Wako Pure Chemical Industries, Ltd. (JP) 2010-11-10 EP disclosed
US-20100176338-A1 Composition Comprising Neopentasilane And Method Of Preparing Same NATA SEMICONDUCTOR MATERIALS CO., LTD. (CN) 2010-07-15 US disclosed
US-20100041916-A1 PROCESS FOR PRODUCTION OF SULFONIC ACID ESTER WAKO PURE CHEMICAL INDUSTRIES, LTD. (JP) 2010-02-18 US disclosed
EP-2076558-A1 COMPOSITION COMPRISING NEOPENTASILANE AND METHOD OF PREPARING SAME Dow Corning Corporation (US) 2009-07-08 EP disclosed
EP-2067770-A1 PROCESS FOR PRODUCTION OF SULFONIC ACID ESTER Wako Pure Chemical Industries, Ltd. (JP) 2009-06-10 EP disclosed
US-20090069546-A1 PYRAZOLE-BASED CYANINE DYE WAKO PURE CHEMICAL INDUSTRIES, LTD. (JP) 2009-03-12 US disclosed
EP-2006289-A1 PYRAZOLE-TYPE CYANINE DYE Wako Pure Chemical Industries, Ltd. (JP) 2008-12-24 EP disclosed
WO-2008051328-A1 COMPOSITION COMPRISING NEOPENTASILANE AND METHOD OF PREPARING SAME DOW CORNING CORPORATION (US) 2008-05-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100041916-A1 PROCESS FOR PRODUCTION OF SULFONIC ACID ESTER SULT1A1, SULT2A1, STS ADH1A 308/4885ADH1C 341/4885ADH4 245/4885
US-20090069546-A1 PYRAZOLE-BASED CYANINE DYE CBR3, CYB5R3, TST ADH1A 2847/4885ADH1C 3114/4885ADH4 654/4885
US-20100324314-A1 PROCESS FOR PRODUCING ESTER COMPOUND ADH1C, ADH5, ADH1A ADH1A 3/4885ADH1C 1/4885ADH4 44/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.